FDA adcomm votes unanimously against Reata's potential Alport syndrome treatment
The US FDA’s Cardiovascular and Renal Drugs Advisory Committee on Wednesday voted 13-0 that the agency should not approve Reata Pharmaceuticals’ bardoxolone methyl capsules as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
